Google30 welcome to the UNI thread.Some advice before jumping...

Google30 welcome to the UNI thread.

Some advice before jumping around with big boots on, do some research and post things that help us all learn more about the market segment or the stock.

UNI are not after a share of the pen market, we are after introducing a safety syringe to the 63% of the USA market that does not use pens but need a safety syringe just like the FDA approved unit we will be mass producing at 40-60M units by June next year.

Look forward to some real comment from you soon, good or bad is fine just make sure its factual and adds value.

Snork

http://www.mendosa.com/insulin_pens.htm

Until now, the 800-pound gorilla in the insulin delivery market has been Becton Dickinson. Its strength is not in pens but in the much larger syringe business where it commands an 80 percent market share, according to Frost & Sullivan data. Becton is only a minor player in the pen devices and pen needle business, well behind Novo.

Becton commands 63 percent of the entire insulin delivery systems market, Frost & Sullivan says. In 1997 Becton's share of that $236.1 million market would have been $148.7 million. Frost & Sullivan projects a 6.6 percent annual growth in the insulin delivery system market.



http://www.mendosa.com/insulin_pens.htm